tetano
Editor, Senior Moderator
Biomed Pharmacother
. 2022 Feb 4;147:112682.
doi: 10.1016/j.biopha.2022.112682. Online ahead of print.
Antiviral effects of azithromycin: A narrative review
Saeed Khoshnood[SUP] 1 [/SUP], Maryam Shirani[SUP] 2 [/SUP], Amine Dalir[SUP] 3 [/SUP], Melika Moradi[SUP] 4 [/SUP], Mohammad Hossein Haddadi[SUP] 1 [/SUP], Nourkhoda Sadeghifard[SUP] 1 [/SUP], Faezeh Sabet Birjandi[SUP] 5 [/SUP], Ilya Yashmi[SUP] 6 [/SUP], Mohsen Heidary[SUP] 7 [/SUP]
Affiliations
Abstract
Viral infections have a great impact on human health. The urgent need to find a cure against different viruses led us to investigations in a vast range of drugs. Azithromycin (AZT), classified as a macrolide, showed various effects on different known viruses such as severe acute respiratory syndrome coronavirus (SARS-CoV), Zika, Ebola, Enterovirus (EVs) and Rhinoviruses (RVs), and Influenza A previously; namely, these viruses, which caused global concerns, are considered as targets for AZT different actions. Due to AZT background in the treatment of known viral infections mentioned above (which is described in this study), in the early stages of COVID-19 (a new zoonotic disease caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) development, AZT drew attention to itself due to its antiviral and immunomodulatory effects as a valuable candidate for COVID-19 treatment. AZT usage instructions for treating different viral infections have always been under observation, and COVID-19 is no exception. There are still debates about the use of AZT in COVID-19 treatment. However, eventually, novel researches convinced WHO to announce the discontinuation of AZT use (alone or in combination with hydroxychloroquine) in treating SARS-CoV-2 infection. This research aims to study the structure of all of the viruses mentioned above and the molecular and clinical effects of AZT against the virus.
Keywords: Azithromycin; COVID-19; Ebola; Enterovirus and Rhinoviruses; Influenza A; SARS-CoV; SARS-CoV-2; Viral infections; Zika.
. 2022 Feb 4;147:112682.
doi: 10.1016/j.biopha.2022.112682. Online ahead of print.
Antiviral effects of azithromycin: A narrative review
Saeed Khoshnood[SUP] 1 [/SUP], Maryam Shirani[SUP] 2 [/SUP], Amine Dalir[SUP] 3 [/SUP], Melika Moradi[SUP] 4 [/SUP], Mohammad Hossein Haddadi[SUP] 1 [/SUP], Nourkhoda Sadeghifard[SUP] 1 [/SUP], Faezeh Sabet Birjandi[SUP] 5 [/SUP], Ilya Yashmi[SUP] 6 [/SUP], Mohsen Heidary[SUP] 7 [/SUP]
Affiliations
- PMID: 35131658
- DOI: 10.1016/j.biopha.2022.112682
Abstract
Viral infections have a great impact on human health. The urgent need to find a cure against different viruses led us to investigations in a vast range of drugs. Azithromycin (AZT), classified as a macrolide, showed various effects on different known viruses such as severe acute respiratory syndrome coronavirus (SARS-CoV), Zika, Ebola, Enterovirus (EVs) and Rhinoviruses (RVs), and Influenza A previously; namely, these viruses, which caused global concerns, are considered as targets for AZT different actions. Due to AZT background in the treatment of known viral infections mentioned above (which is described in this study), in the early stages of COVID-19 (a new zoonotic disease caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) development, AZT drew attention to itself due to its antiviral and immunomodulatory effects as a valuable candidate for COVID-19 treatment. AZT usage instructions for treating different viral infections have always been under observation, and COVID-19 is no exception. There are still debates about the use of AZT in COVID-19 treatment. However, eventually, novel researches convinced WHO to announce the discontinuation of AZT use (alone or in combination with hydroxychloroquine) in treating SARS-CoV-2 infection. This research aims to study the structure of all of the viruses mentioned above and the molecular and clinical effects of AZT against the virus.
Keywords: Azithromycin; COVID-19; Ebola; Enterovirus and Rhinoviruses; Influenza A; SARS-CoV; SARS-CoV-2; Viral infections; Zika.